21st week of 2014 patent applcation highlights part 38 |
Patent application number | Title | Published |
20140141006 | HUMAN MONOCLONAL ANTIBODIES TO EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) - Isolated human monoclonal antibodies which specifically bind to human EGFR, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies. | 2014-05-22 |
20140141007 | STABLE HIGH PROTEIN CONCENTRATION FORMULATIONS OF HUMAN ANTI-TNF-ALPHA-ANTIBODIES - The invention provides a liquid pharmaceutical formulation which does not include NaCl and comprises more than 20 mg of a polyol and at least about 100 mg/mL of a human anti-TNF-alpha antibody, or antigen-binding portion thereof. The invention provides a high concentration antibody formulation having long-term stability and advantageous characteristics for subcutaneous administration. | 2014-05-22 |
20140141008 | STABLE HIGH PROTEIN CONCENTRATION FORMULATIONS OF HUMAN ANTI-TNF-ALPHA-ANTIBODIES - The invention provides a liquid pharmaceutical formulation which does not include NaCl and comprises more than 20 mg of a polyol and at least about 100 mg/mL of a human anti-TNF-alpha antibody, or antigen-binding portion thereof. The invention provides a high concentration antibody formulation having long-term stability and advantageous characteristics for subcutaneous administration. | 2014-05-22 |
20140141009 | USE OF ANTAGONISTS TARGETING METALLOTHIONEIN TO TREAT INTESTINAL INFLAMMATION - Metallothioneins are stress inducible proteins with modulating functions during inflammation. Antagonizing metallothioneins during gut inflammation reduces markers of inflammations and enhances recuperation of intestinal inflammation. | 2014-05-22 |
20140141010 | USE OF ADSL ACTIVATOR TO ACHIEVE GLYCEMIC CONTROL IN MAMMALS - The embodiments disclosed here in relates to use of activators of ADSL for the production of pharmaceutical agents to achieve glycemic control in mammals and which are therefore useful in the treatment of certain disorders that can be prevented or treated by activation of this enzyme. | 2014-05-22 |
20140141011 | ENGINEERED ANTI-TSLP ANTIBODY - The invention relates to binding compounds that specifically bind to human TSLP, as well as uses thereof, e.g., in the treatment of inflammatory disorders. | 2014-05-22 |
20140141012 | ENGINEERED ANTI-TSLP ANTIBODY - The invention relates to binding compounds that specifically bind to human TSLP, as well as uses thereof, e.g., in the treatment of inflammatory disorders and allergic inflammatory response. | 2014-05-22 |
20140141013 | ANTI-IL-6 ANTIBODIES, COMPOSITIONS, METHODS AND USES - The present invention relates to at least one novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices. | 2014-05-22 |
20140141014 | ANTIBODIES THAT INHIBIT METALLOPROTEINS - An antibody is disclosed which comprises an antigen recognition region which comprises six CDR amino acid sequences selected from the group consisting of SEQ ID NOs: 4-15. Uses thereof are also disclosed. | 2014-05-22 |
20140141015 | QSOX1 as an Anti-Neoplastic Drug Target - The present invention provides methods for tumor treatment by administering an inhibitor of quiescin sulfhydryl oxidase 1 (QSOX1), compositions comprising such inhibitors, and methods for identifying such inhibitors. | 2014-05-22 |
20140141016 | ANTIBODIES TO CD70 - The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth. | 2014-05-22 |
20140141017 | METHODS OF DIAGNOSING ATHEROSCLEROSIS BY MEASURING APOCI - The present invention provides methods and compositions for identifying compounds which inhibit ApoCI and which are useful in the treatment or prevention of atherosclerosis, plaque rupture, apoptosis, or myocardial infarction. The invention further provides methods for treating subjects suffering from or at risk of developing atherosclerosis, plaque rupture, apoptosis, or myocardial infarction. The invention further provides methods for diagnosing subjects at suffering from or at risk of developing treatment or prevention of atherosclerosis, plaque rupture, apoptosis, or myocardial infarction. | 2014-05-22 |
20140141018 | ANTAGONIST ANTI-IL-7 RECEPTOR ANTIBODIES AND METHODS - The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (IL-7R). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof for the treatment and/or prevention of type 2 diabetes and immunological disorders, including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, graft-versus-host disease, and lupus. | 2014-05-22 |
20140141019 | ANTIBODIES AGAINST HER3 - The invention relates to antibodies against HER3 and their use in the treatment of cancer. | 2014-05-22 |
20140141020 | ANTI-CD3 THERAPIES - This document provides methods and materials related to anti-CD3 therapies. For example, anti-CD3γε antibody preparations as well as methods and materials for using anti-CD3γε antibody preparations to reduce a T cell-mediated immune response within a mammal are provided. | 2014-05-22 |
20140141021 | METHOD FOR PREPARING A CONCENTRATE OF POLYVALENT IMMUNOGLOBULIN - The present invention relates to a method for preparing a concentrate of polyvalent immunoglobulins with view to therapeutic use, from an initial solution of blood plasma or a plasma fraction enriched with immunoglobulins, comprising the steps for removing the protein contaminants by precipitation with caprylic acid in order to obtain a solution free of proteases, and for separating by chromatography on a fluidized bed the solution free of proteases, said method allowing a concentrate of human polyvalent immunoglobulins with a yield of more than 4.5 g of immunoglobulins per liter of blood plasma applied to be obtained. | 2014-05-22 |
20140141022 | SINGLE-CHAIN MULTIVALENT BINDING PROTEINS WITH EFFECTOR FUNCTION - Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition. | 2014-05-22 |
20140141023 | NOVEL ANTIGEN BINDING PROTEIN AND ITS USE AS ADDRESSING PRODUCT FOR THE TREATMENT OF CANCER - The present invention relates to a novel antigen binding protein, in particular a monoclonal antibody, capable of binding specifically to the protein Axl as well as the amino and nucleic acid sequences coding for said protein. From one aspect, the invention relates to a novel antigen binding protein, or antigen binding fragments, capable of binding specifically to Axl and, by inducing internalization of Axl, being internalized into the cell. The invention also comprises the use of said antigen binding protein as an addressing product in conjugation with other anti-cancer compounds, such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers. | 2014-05-22 |
20140141024 | COMBINATION OF ANTI-CTLA4 ANTIBODY WITH DIVERSE THERAPEUTIC REGIMENS FOR THE SYNERGISTIC TREATMENT OF PROLIFERATIVE DISEASES - Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders. | 2014-05-22 |
20140141025 | HYDRAZINYL-INDOLE COMPOUNDS AND METHODS FOR PRODUCING A CONJUGATE - The present disclosure provides conjugate structures (e.g., polypeptide conjugates) and hydrazinyl-indole compounds used to produce these conjugates. The disclosure also provides methods of production of such conjugates, as well as methods of using the same. | 2014-05-22 |
20140141026 | GENERATION OF ANTIGEN SPECIFIC T CELLS - The present invention is directed to a method of generating antigen specific T cells. Furthermore, the invention is directed to antigen specific T cells, isolated transgenic TCR's, pharmaceutical compositions containing same and their use in adoptive cell therapy. This invention in particular pertains to the use of cells co-expressing allogeneic MHC molecules and antigens to induce peptide-specific T cells from non-selected allogeneic T cell repertoires. | 2014-05-22 |
20140141027 | PEPTIDE VACCINES FOR CANCERS EXPRESSING TUMOR-ASSOCIATED ANTIGENS - The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 19, 22, 30, 34, 344, 358, 41, 44, 46, 48, 78, 376, 379, 80, 100, 101, 110, 111, 387, 112, 394, 114, 116, 117, 121, 395, 133, 135, 137, 426, 143, 147, 148, 149, 150, 152, 153, 154, 156, 160, 161, 162, 163, 166, 174, 178, 186, 194, 196, 202, 210, 213, 214, 217, 223, 227, 228, 233, 254, 271, 272 or 288, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several (e.g., up to 5) amino acids are substituted, deleted, or added, provided the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with over-expression of the CDH3, EPHA4, ECT2, HIG2, INHBB, KIF20A, KNTC2, TTK and/or URLC10, e.g. cancers containing as an active ingredient one or more of these peptides. The peptides of the present invention find further utility as vaccines. | 2014-05-22 |
20140141028 | MELK EPITOPE PEPTIDES AND VACCINES CONTAINING THE SAME - According to the present invention, peptides having the amino acid sequence of SEQ ID NOs: 14, 21, 23, 27, 36, 46, 57, 60 and 62 were demonstrated to have cytotoxic T lymphocyte (CTL) inducibility. Therefore, the present invention provides a peptide having the amino acid sequence selected from among SEQ ID NOs: 14, 21, 23, 27, 36, 46, 57, 60 and 62. The peptide can include one, two, or several amino acid substitutions, deletions, insertions, or additions so long as its CTL inducibility is retained. Furthermore, the present invention provides pharmaceutical agents for the treatment and/or prophylaxis of cancers, and/or prevention of postoperative recurrence thereof, which contain any of these peptides. Pharmaceutical agents of this invention include vaccines. | 2014-05-22 |
20140141029 | CHIMERIC OSPA GENES, PROTEINS AND METHODS OF USE THEREOF - The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of | 2014-05-22 |
20140141030 | CHIMERIC OSPA GENES, PROTEINS AND METHODS OF USE THEREOF - The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of | 2014-05-22 |
20140141031 | PATHOGENIC BACTERIA - The invention provides novel surface coat proteins of | 2014-05-22 |
20140141032 | TEMPO-mediated glycoconjugation of immunogenic composition against Campylobacter jejuni with improved structural integrity and immunogenicity - Immunogenic capsule polysaccharide polymer composition, and its method of producing, with improved structural integrity and immunogenic properties. The invention also relates to a method of using the compositions to elicit an immune response to | 2014-05-22 |
20140141033 | CONJUGATED TLR7 AND/OR TLR8 AND TLR2 AGONISTS - A conjugated compound of formula Q-Z—R | 2014-05-22 |
20140141034 | TYROSINE LIGATION PROCESS - A process is provided for preparing a conjugate of Formula (I-A) or (I) comprising a polypeptide containing n number of tyrosine units, where n is an integer greater than or equal to 1, dispersed within the amino acid chain | 2014-05-22 |
20140141035 | Cosmetic Compositions Comprising Marine Plants - The present invention relates to a cosmetic active ingredient for improving the appearance of the skin beneath the eyes. More particularly, the present invention relates to a cosmetic active ingredient comprising an extract of the marine algae, | 2014-05-22 |
20140141036 | In Vivo Activation of Antigen Presenting Cells for Enhancement of Immune Responses Induced by Virus Like Particles - The invention relates to the finding that stimulation of antigen presenting cell (APC) activation using substances such as anti-CD40 antibodies or DNA oligomers rich in non-methylated C and G (CpGs) can dramatically enhance the specific T cell response obtained after vaccination with recombinant virus like particles (VLPs) coupled, fused or otherwise attached to antigens. While vaccination with recombinant VLPs fused to a cytotoxic T cell (CTL) epitope of lymphocytic choriomeningitis virus induced low levels cytolytic activity only and did not induce efficient anti-viral protection, VLPs injected together with anti-CD40 antibodies or CpGs induced strong CTL activity and full anti-viral protection. Thus, stimulation of APC-activation through antigen presenting cell activators such as anti-CD40 antibodies or CpGs can exhibit a potent adjuvant effect for vaccination with VLPs coupled, fused or attached otherwise to antigens. | 2014-05-22 |
20140141037 | RSV F PREFUSION TRIMERS - Complexes that contain RSV F ectodomain polypeptides and methods for making the complexes are disclosed. The RSV F ectodomain polypeptides can be in the prefusion form. | 2014-05-22 |
20140141038 | CMV GLYCOPROTEINS AND RECOMBINANT VECTORS - Disclosed herein are recombinant CMV vectors which may comprise a heterologous antigen that can repeatedly infect an organism while inducing a CD8+ T cell response to immunodominant epitopes of the heterologous antigen. The CMV vector may comprise a deleterious mutation in the US 11 glycoprotein or a homolog thereof. | 2014-05-22 |
20140141039 | Biomarker for Monitoring Patients - The present invention is in the field of immunotherapy and relates to methods for determining the efficacy of certain immunotherapy treatments. The methods of the invention include measuring special biomarker at some time following the initiation of immunotherapy treatment to evaluate the clinical outcome of the said treatment. The invention thus has applications to the field of medicine. | 2014-05-22 |
20140141040 | AVIRULENT, IMMUNOGENIC FLAVIVIRUS CHIMERAS - Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses. | 2014-05-22 |
20140141041 | RAPID AND PROLONGED IMMUNOLOGIC-THERAPEUTIC - The present invention shows that intranasal administration of E1/E3-defective adenovirus particles may confer rapid and broad protection against viral and bacterial pathogens in a variety of disease settings. Protective responses lasted for many weeks in a single-dose regimen in animal models. When a pathogen-derived antigen gene was inserted into the E1/E3-defective adenovirus genome, the antigen-induced protective immunity against the specific pathogen was elicited before the adenovirus-mediated protective response declined away, thus conferring rapid, prolonged, and seamless protection against pathogens. In addition to E1/E3-defective adenovirus, other bioengineered non-replicating vectors encoding pathogen-derived antigens may also be developed into a new generation of rapid and prolonged immunologic-therapeutic (RAPIT). | 2014-05-22 |
20140141042 | Expression Systems - The invention relates to an expression system comprising polynucleotides encoding proteins, wherein the expression system comprises a first polynucleotide encoding at least one protein, peptide or variant thereof, which induces a T cell response, and a second polynucleotide encoding at least one protein peptide or variant thereof, which induces an anti-pathogenic B cell response. The invention further relates to protein mixtures encoded by the expression system and cells comprising the expression system or the protein mixture and pharmaceutical compositions comprising the expression system or the protein mixture. The expression system, polynucleotides, proteins, cells, and pharmaceutical compositions are useful in the prophylaxis or treatment of infections. The invention further relates to nucleotide constructs which comprises, essentially consists or consists of a polynucleotide encoding a modified influenza hemagglutinin (HA). | 2014-05-22 |
20140141043 | COMPOSITIONS, VECTORS, KITS, AND METHODS FOR IMMUNIZING AGAINST AVIAN INFECTIOUS BRONCHITIS VIRUS - Disclosed are compositions, vectors, kits, and methods for inducing an immune response against avian infectious bronchitis virus (IBV). In particular, the compositions, vectors, kits, and methods may be utilized to immunize poultry against disease associated with IBV infection or to protect poultry from IBV infection altogether. | 2014-05-22 |
20140141044 | Cord Colitis Syndrome Pathogen - The present invention provides a novel cord colitis syndrome pathogen as well as a method for the discovery of novel viral, prokaryotic or eukaryotic genomes or genomic fragments using a sequencing-based methodology. | 2014-05-22 |
20140141045 | Allogeneic Tumor Cell Vaccination - The present invention relates to cancer immunotherapy, specifically to allogeneic tumor cell vaccines. According to some embodiments, the invention provides novel cell lines useful as therapeutic cell vaccine compositions. The invention further provides advantageous screening methods and means for identifying patients amenable for treatment with partially Human Leukocyte Antigen (HLA) matched allogeneic cell vaccines. Therapeutic compositions and methods for use in proliferative disorders are further provided. | 2014-05-22 |
20140141046 | METHOD AND COMPOSITION FOR PRODUCING A CELLULAR ALLOGENEIC VACCINE - The present invention relates to a method for the production of a cellular allogeneic vaccine, which is based upon an allogeneic APC, comprising the following steps:
| 2014-05-22 |
20140141047 | SELECTION OF PLATELET RICH PLASMA COMPONENTS VIA MINERAL BINDING - Mineral coated devices and methods for delivering an autologous biological molecule using the mineral coated devices are disclosed. The mineral coated devices allow for the isolation and delivery of a biological molecule obtained from the same subject to avoid the safety concerns of current biological therapies obtained by recombinant methods and purification from animal sources. Methods for selectively isolating and eluting a biological molecule using the mineral coated devices are also disclosed. | 2014-05-22 |
20140141048 | IONIC HYDROPHILIC POLYMER COATINGS FOR USE IN MEDICAL DEVICES - According to one aspect of the disclosure, medical devices are provided which have a negatively charged surface and a lubricous hydrophilic coating comprising a sulf(on)ated species disposed on the negatively charged surface. In various embodiments, the sulf(on)ated species is ionically crosslinked with itself and with the negatively charged species by a multivalent cationic species. In other aspects, medical devices are provided which have a polymeric surface and a lubricous hydrophilic layer comprising a covalently crosslinked sulf(on)ated species disposed on the surface. Still other aspects of the invention pertain to methods of forming such devices and methods of using such devices. | 2014-05-22 |
20140141049 | METHOD AND COMPOSITION FOR IMPROVING SKIN CONDITIONS COMPRISING HUMAN PLACENTAL LACTOGEN AS AN ACTIVE INGREDIENT - Disclosed herein is a skin condition-improving composition for topical application to the skin, comprising human placental lactogen (hPL) as an active ingredient. The disclosed method and composition exhibit various skin-conditioning effects, such as preventing and/or reducing atopic dermatitis, ultraviolet-light-caused skin damage, wrinkles, age spots, skin pigmentation, acne, itching, xerosis, and skin aging; and such as improving skin elasticity and moisturization. | 2014-05-22 |
20140141050 | BIORESORBABLE WOUND DRESSING - The present invention is directed to novel non-woven fabrics containing growth and differentiation factor proteins. Said fabrics are specifically designed to accelerate tissue regeneration and wound healing processes of mammalian tissues. Furthermore, the invention provides wound dressings, pads or implants comprising the novel non-woven fabrics. | 2014-05-22 |
20140141051 | Dispenser - Dispensers for dispensing an insect control active include a porous substrate impregnated with an insect control active. The porous substrate has a minimal bending moment of about 150 to about 275 g-cm. Upon activation, the dispenser exhibits an effective release rate of the insect control active of about 0.1 to about 0.3 mg/hr. | 2014-05-22 |
20140141052 | SUBSTRATE HAVING AN ELECTRON DONATING SURFACE WITH METAL PARTICLES COMPRISING PALLADIUM ON SAID SURFACE - There is disclosed a substrate with an electron donating surface, characterized in having metal particles on said surface, said metal particles comprising palladium and at least one metal selected from the group consisting of gold, ruthenium, rhodium, osmium, iridium, and platinum, wherein the amount of said metal particles is from about 0.001 to about 8 μg/cm | 2014-05-22 |
20140141053 | MICROLAYER COEXTRUSION TO CREATE A TIME-RELEASE DRUG SUBSTANCE DELIVERY PRODUCT - The present invention relates to medical devices containing time-release drug substance, and more particularly, to medical tubing, catheters, stents, cables (including fiber optic cables), pills, capsules, sheaths, threads, clamps, sutures, and endotracheal devices. The invention also generally relates to a method for extruding multiple laminated flow streams using microlayer coextrusion to create these various time-release drug delivery products. | 2014-05-22 |
20140141054 | PARTICULATE TISSUE GRAFT WITH COMPONENTS OF DIFFERING DENSITY AND METHODS OF MAKING AND USING THE SAME - Disclosed are tissue graft compositions made of particles having different densities, methods of making these compositions, and methods of using these compositions for promoting tissue restoration in a patient. | 2014-05-22 |
20140141055 | MANUFACTURING OF SEMI-PLASTIC PHARMACEUTICAL DOSAGE UNITS - A process for the manufacture of semi-plastic pharmaceutical unit doses using a rotary moulding machine and semi-plastic pharmaceutical dosage units obtained by this process. | 2014-05-22 |
20140141056 | LIDOCAINE-CONTAINING HYDROGEL PATCH - A lidocaine-containing hydrogel patch comprising:
| 2014-05-22 |
20140141057 | Adhesive or Hydrocolloid Containing Vegetable Oil - Various compositions including vegetable oil are described. The compositions also include either or both of an adhesive component and a hydrocolloid component. The vegetable oil imparts a skin-soothing property in the resulting compositions. The compositions can be used in a wide range of medical products and consumer healthcare goods. | 2014-05-22 |
20140141058 | USE OF OLIGOSACCHARIDE COMPOUNDS FOR THE PREVENTION AND TREATMENT OF PATHOLOGICAL SCARS - The present invention relates to a compound selected among the synthetic polysulphated oligosaccharides having 1 to 4 ose units and the salts and complexes thereof to be used for the treatment of wounds resulting in pathological scars selected among hypertrophic, retractile or atrophic scars. Said use is preferred in particular in patients that have a predisposition to developing hypertrophic, retractile or atrophic scars. According to a second aspect, the invention also relates to said compound for the use thereof in order to inhibit the differentiation of fibroblasts into myofibroblasts during the cicatrisation of wounds resulting in pathological scars selected among hypertrophic, retractile or atrophic scars. | 2014-05-22 |
20140141059 | PATCH - Provided is a patch that ensures high storage stability of donepezil or a salt thereof and allows stable transdermal administration of the donepezil or salt thereof in an amount that provides a pharmaceutical effect. The patch includes a substrate | 2014-05-22 |
20140141060 | COMPOSITIONS AND METHODS FOR PROTECTING CELLS DURING CANCER CHEMOTHERAPY AND RADIOTHERAPY - Compositions, pharmaceutical preparations and methods are disclosed for protecting non-neoplastic cells from damage caused by cancer chemotherapeutic agents or radiation therapy, during the course of cancer therapy or bone marrow transplant. These are based on the use of chemoprotective inducing agents that induce or increase production of cellular detoxification enzymes in target cell populations. The compositions and methods are useful to reduce or prevent hair loss, gastrointestinal distress and lesions of the skin and oral mucosa that commonly occur in patients undergoing cancer therapy. Also disclosed is a novel assay system for identifying new chemoprotective inducing agents. | 2014-05-22 |
20140141061 | Use of WNT Agents to Prevent Hypoxic Injury - Methods and compositions are provided for the therapeutic use of Wnt proteins or Wnt agonists in protecting tissue from the adverse effects of hypoxia. | 2014-05-22 |
20140141062 | COMPOSITIONS AND METHODS FOR TREATMENT - The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists. | 2014-05-22 |
20140141063 | HYDROGEL - The invention is related to gel preparations capable of absorbing as well as releasing liquid, and the use of such gel preparations in the treatment of wounds. | 2014-05-22 |
20140141064 | HLA-A2 TUMOR ASSOCIATED ANTIGEN PEPTIDES AND COMPOSITIONS - A peptide or composition comprising at least one HLA-A2 epitope or analog from CEA, HER2/neu, MAGE2, MAGE3, or p53. | 2014-05-22 |
20140141065 | METHOD TO ACHIEVE EXTENDED EXPRESSION OF DNA INFUSED INTO LIVER - Materials and methods for treating a patient to express a therapeutic agent comprising administering a Kupffer cell-suppressing substance in combination with a vehicle for introducing, into the patient, an exogenous nucleic acid comprising a sequence for expression of the agent. | 2014-05-22 |
20140141066 | Encapsulated Ascorbic Acid Composition - An encapsulated ascorbic acid composition is a formulation that protects the encapsulated ascorbic acid from unwanted interactions and significantly reduces the likelihood of an unwanted allergic reaction for many users. The encapsulated ascorbic acid composition accomplishes this through the use of sunflower lecithin. Sunflower lecithin is utilized as carrier material that forms the liposomal barrier surrounding a quantity of the ascorbic acid. Sunflower lecithin does not contain common allergens, allowing for increased accessibility of the encapsulated ascorbic acid composition. Additionally, the sunflower lecithin contains a higher quantity of the phospholipid, phosphatidylcholine, compared to other lecithin sources. Phosphatidylcholine is readily absorbed increasing the bioavailability of ascorbic acid in a user. Furthermore, high quantities of phosphatidylcholine form smaller, more stable, and more uniformly shaped liposome resulting in better absorption. | 2014-05-22 |
20140141067 | MODIFIED POLYNUCLEOTIDES ENCODING SEPTIN-4 - The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of oncology-related polynucleotides, oncology-related primary transcripts and oncology-related mmRNA molecules. | 2014-05-22 |
20140141068 | MODIFIED POLYNUCLEOTIDES ENCODING SIAH E3 UBIQUITIN PROTEIN LIGASE 1 - The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of oncology-related polynucleotides, oncology-related primary transcripts and oncology-related mmRNA molecules. | 2014-05-22 |
20140141069 | BETA-GUANIDINOPROPIONIC ACID FOR THE TREATMENT OF HYPERTENSION - The present invention relates to β-guanidinopropionic acid for the prevention and/or treatment of hypertension associated with high baseline creatine kinase levels, not necessarily associated with hyperglycemia, impaired glucose tolerance, hyperinsulinemia, insulin insensitivity, hyperamilinemia, excess adiposity or hyperlipidemia, comprising administering to a subject in need thereof a therapeutically effective dosage of a pharmaceutical composition comprising β-guanidinopropionic acid, or a pharmaceutically acceptable salt or derivative thereof, and a pharmaceutically acceptable carrier. | 2014-05-22 |
20140141070 | LIPOSOMES HAVING USEFUL N:P RATIO FOR DELIVERY OF RNA MOLECULES - Nucleic acid immunisation is achieved by delivering a RNA encapsulated within a liposome comprising a cationic lipid, wherein the liposome and the RNA have a N:P ratio of between 1:1 and 20:1. | 2014-05-22 |
20140141071 | ORALLY ADMINISTRABLE LIPOSOMALLY ENCAPSULATED REDUCED GLUTATHIONE, WITH N-O ENHANCING COMPOUNDS FOR REVERSAL AND PREVENTION OF OXIDATION OF CHOLESTEROL AND OF LOW DENSITY LIPOPROTEIN - The invention proposes the sure of reduced glutathione in a liposome (liposomal reduced glutathione) for the oral administration of a therapeutically effective amount to ameliorate the progression of vascular disease, including atherosclerosis, diabetes, hypertension, narrowing of arteries leading to decreased blood flow, ischemic events, and the formation of blood clots, abnormal platelet aggregation, and thrombotic events, by reducing the amount and effect of oxidized cholesterol, oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with statin drugs to improve the effect of lowering not only cholesterol but also the oxidized cholesterol as well as oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with CoQ10 as a therapy for vascular disease and management of side effects of statin therapy. | 2014-05-22 |
20140141072 | LYOPHILIZING COMPOSITION OF DRUG-ENCAPSULATING POLYMER MICELLE AND METHOD FOR PREPARATION THEREOF - Provided are a composition for preparing a lyophilized preparation, comprising a drug-encapsulating polymer micelle and saccharides and/or polyethylene glycol as a stabilizing agent, a lyophilized preparation and a process for producing them. The lyophilized preparation thus provided is easily restructured to an aqueous preparation using an aqueous medium. | 2014-05-22 |
20140141073 | ANTI-VIRUS HYDROPHILIC POLYMERIC MATERIAL - The invention provides a method for imparting antiviral properties to a hydrophilic polymeric material comprising preparing a hydrophilic polymeric slurry, dispersing an ionic copper powder mixture containing cuprous oxide and cupric oxide in said slurry and then extruding or molding said slurry to form a hydrophilic polymeric material, wherein water-insoluble particles that release both Cu | 2014-05-22 |
20140141074 | CONCENTRATED THERAPEUTIC PHOSPHOLIPID COMPOSITIONS - The invention relates to concentrated therapeutic phospholipid compositions; methods for treating or preventing diseases associated with cardiovascular disease, metabolic syndrome, inflammation and diseases associated therewith, neurodevelopmental diseases, and neurodegenerative diseases, comprising administering an effective amount of a concentrated therapeutic phospholipid composition. | 2014-05-22 |
20140141075 | 5-AMINOSALICYLIC ACID CAPSULE FORMULATION - A dosage form comprising a capsule containing one or more tablets of 5-aminosalicylic acid or a salt thereof as an active ingredient where each of the one or more tablets is enterically coated is disclosed. | 2014-05-22 |
20140141076 | SOFT CAPSULE PREPARATION, COMPOSITION FOR SOFT CAPSULE PREPARATION, AND METHOD OF PRODUCING SOFT CAPSULE PREPARATION - The present invention provides: a soft capsule preparation which includes a self-emulsifying composition containing an oily component, an emulsifier, 8% by mass to 20% by mass of a polyhydric alcohol and 2.5% by mass to 5% by mass of water, and a capsule film containing 35% by mass to 50% by mass of a polyhydric alcohol and gelatin, in which capsule film the above-described self-emulsifying composition is encapsulated; a method of producing the soft capsule preparation; a composition for a soft capsule preparation, which is an intermediate product of the soft capsule preparation; and a self-emulsifying composition and a capsule film composition that are used in the composition for a soft capsule preparation. | 2014-05-22 |
20140141077 | COMPOSITION FOR USE IN TREATING AND PREVENTING INFLAMMATION RELATED DISORDER - The present invention is related to a use for treating and preventing inflammation related disorder of a composition containing a drug and hyaluronic acid (HA) or HA mixture, whereas the HA or the HA mixture as a delivery vehicle can be a formulation including at least two HAs having different average molecular weights. The composition has been demonstrated to be capable of reducing the therapeutic dose of a drug on the treatment and prevention of inflammation related disorders is acute inflammatory disease, chronic obstructed pulmonary disease, coeliac disease, conjunctivitis, otitis, allergic rhinitis, gingivitis, aphthous ulcer, bronchitis, gastroesophageal reflux disease (GERD), esophagitis, gastritis, enteritis, peptic ulcer, inflammatory bowel disease (IBD), Crohn's Disease, irritable bowel syndrome (IBS), intestinal inflammation or allergy, urethritis, cystitis, vaginitis, proctitis, eosinophilic gastroenteritis, or rheumatoid arthritis. | 2014-05-22 |
20140141078 | Dissolvable TableT - A dissolvable tablet is disclosed. The tablet includes a front side, an obverse side and a thickness between the front side and the obverse side. The front side and obverse side have a variation of convex and concave surfaces. The convex and concave surfaces allow for a plurality of dissolvable tablets to be stacked for packaging. Further, the variation of convex and concave surfaces allow for a self-agitation when the dissolvable tablet is dissolved within a liquid. | 2014-05-22 |
20140141079 | PRAMIPEXOLE ONCE-DAILY DOSAGE FORM - An orally deliverable pharmaceutical composition comprises a therapeutically effective amount of pramipexole or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, said composition exhibiting at least one of (a) an in vitro release profile wherein on average no more than about 20% of the pramipexole is dissolved within 2 hours after placement of the composition in a standard dissolution test; and (b) an in vivo pramipexole absorption profile following single dose administration to healthy adult humans wherein the time to reach a mean of 20% absorption is greater than about 2 hours and/or the time to reach a mean of 40% absorption is greater than about 4 hours. The composition is useful for oral administration, not more than once daily, to a subject having a condition or disorder for which a dopamine receptor agonist is indicated. | 2014-05-22 |
20140141080 | PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDS - The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages. | 2014-05-22 |
20140141081 | FORMS OF RIFAXIMIN AND USES THEREOF - The present invention relates to Rifaximin polymorphic, salt, hydrate, and amorphous forms, to their use in medicinal preparations and to therapeutic methods using them. | 2014-05-22 |
20140141082 | Compositions Containing Enriched Natural Crocin and/or Crocetin, and Their Therapeutic or Nutraceutical Uses - The invention relates to unique compositions containing enriched and purified natural crocin and/or crocetin for prevention and/or treatment of cancers and other conditions and diseases. Compositions comprise mainly enriched or purified natural crocin or crocetin or combination of both and possible other active phytochemicals. A composition is used as functional food, drink, dietary supplement, or therapeutic dosage to a human orally or through other appropriate way (parenteral, percutaneous, rectal, mucosal, intranasal or topical administration). A method of natural crocin and crocetin enriching and purification is revealed. | 2014-05-22 |
20140141083 | NANOPARTICULATE MELOXICAM FORMULATIONS - The present invention is directed to nanoparticulate compositions comprising meloxicam particles having an effective average particle size of less than about 2000 nm. | 2014-05-22 |
20140141084 | HYPOXIA-RESPONSIVE NANOPARTICLE FOR THERAPY AND IMAGING OF HYPOXIA-INVOLVING DISEASES - The present invention relates to an amphiphilic polymer whose property and structure can change under hypoxic conditions, and to nanoparticles formed by self-assembly of the amphiphilic polymer. The hypoxia-responsive nanoparticles according to the present invention release a drug selectively under hypoxic conditions. Thus, the nanoparticles can be used for the selective diagnosis and treatment for diseases that are accompanied by hypoxia. Particularly, the nanoparticles can release a drug only to a targeted tumor in cancer therapy, and thus have minimized side effects and maximized therapeutic effects. | 2014-05-22 |
20140141085 | TRACER PARTICLES, AND METHODS FOR MAKING SAME - The invention relates generally to tracer particles for product identification and/or authentication. When incorporated into a manufactured item, that item can be subsequently authenticated by either detecting, or failing to detect, the tracer particle. The tracer particles of the invention are magnetically attractable, with micromarkings, and in some embodiments, are manufactured with food grade materials and of a particle size suitable for ingestion by humans. The particles can be analyzed qualitatively or quantitatively. In other aspects, the invention provides methods for the manufacture of the tracer particles, and in other aspects, provides methods for using the particles. Examples of products that can be tagged using the tracer particles of the invention include pharmaceuticals, animal feeds or feed supplements, and baby formula. Other applications include forensics, such as in explosive materials. | 2014-05-22 |
20140141086 | Injectable Depot Compositions and Uses Thereof - Injectable depot compositions are provided that include a bioerodible, biocompatible polymer, a solvent having a miscibility in water of less than or equal to 7 wt. % at 25° C., in an amount effective to plasticize the polymer and form a gel therewith, a thixotropic agent, and a beneficial agent. The solvent comprises an aromatic alcohol, an ester of an aromatic acid, an aromatic ketone, or mixtures thereof. The compositions have substantially improved the shear thinning behavior and reduced injection force, rendering the compositions readily implanted beneath a patients body surface by injection. | 2014-05-22 |
20140141087 | Oral Composition Comprising An Antacid, an Anaesthetic and an Inorganic Matrix Comprising Silicon Dioxide and Titanium Dioxide - The invention provides an oral composition comprising a pharmaceutically acceptable carrier, at least one antacid, an inorganic matrix comprising at least silicon dioxide and titanium dioxide, and an anaesthetic, wherein the composition is substantially evenly dispersed in the carrier and is palatable. | 2014-05-22 |
20140141088 | Water-Soluble Anti-Inflammatory Cream with Natural Ingredients Base - A water-soluble anti-inflammatory cream is disclosed. The cream is a composition of between about 7.5% and about 30% by weight of a healing oil; between about 1% and about 6% by weight of an herbal extract; between about 0% and about 3.5% by weight of microencapsulated amino acids; and at least 39.4% by weight water. | 2014-05-22 |
20140141089 | Nanoparticles, Compositions Thereof, and Methods of Use, and Methods of Making the Same - The disclosure is directed to a nanoparticle comprising a porous framework core including a porous framework material and a compound, and a lipid layer disposed on the surface of the porous framework core. | 2014-05-22 |
20140141091 | FEXOFENADINE MICROCAPSULES AND COMPOSITIONS CONTAINING THEM - The present invention provides a pharmaceutical composition comprising taste-masked immediate release microcapsules which comprise fexofenadine and a water-insoluble polymer coating. These microcapsules and the pharmaceutical compositions comprising them have suitable drug content and desirable pharmaceutical properties, including a quick dissolution rate of fexofenadine combined with a taste masking effect. | 2014-05-22 |
20140141092 | GASTRIC RESISTANT PHARMACEUTICAL OR NUTRACEUTICAL COMPOSITION WITH RESISTANCE AGAINST THE INFLUENCE OF ETHANOL - The invention discloses a gastric resistant pharmaceutical or nutraceutical composition, comprising a core, comprising a pharmaceutical or nutraceutical active ingredient and a gastric resistant coating layer onto the core, wherein the gastric resistant coating layer comprises at least 30% by weight of a (meth)acrylate copolymer comprising polymerized units of 10 to 40% by weight of acrylic or methacrylic acid, 10 to 80% by weight of a C | 2014-05-22 |
20140141093 | POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS AND ANTAGONISTS - The invention relates to anti-TNFR1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating inflammatory disease, such as arthritis or COPD. | 2014-05-22 |
20140141094 | SOLID COMPOSITIONS FOR PHARMACEUTICAL USE - The invention relates to solid compositions that may be suitable for administering a therapeutic agent to a subject. The invention also relates to methods of making such solid compositions. The invention further relates to methods of treating a disease, condition, or disorder by administering to a subject such solid compositions. | 2014-05-22 |
20140141095 | USE OF DEUTERIUM DEPLETED WATER FOR THE TREATMENT OF INSULIN RESISTANCE - The invention relates deuterium depleted water containing 0.01 to 135 ppm deuterium, preferably 105 to 125 ppm deuterium, for use in the treatment of insulin resistance. | 2014-05-22 |
20140141096 | Cross-linked collagen comprising an antifungal agent - The disclosure describes collagen constructs comprising antifungal agents, preferably, copper, and related methods. | 2014-05-22 |
20140141097 | ANTISEPTIC POLYMETHYLMETHACRYLATE BONE CEMENT - The invention proposes an antiseptic composition for use as bone cement, in particular an antiseptic polymethylmethacrylate bone cement, that can be cured and comprises a content of at least one component that is a compound with an oxidising effect or from which a compound with an oxidising effect can be released. Preferably, hydrogen peroxide is or can be released. In this context, it is particularly preferred to use an adduct or a salt of hydrogen peroxide that releases hydrogen peroxide in the presence of water or aqueous conditions. The antiseptic polymethylmethacrylate bone cement can be used for mechanical fixation of primary total articular endoprostheses, for mechanical fixation of revision total articular endoprostheses, and for producing spacers. | 2014-05-22 |
20140141098 | USE OF INHALED GASEOUS NITRIC OXIDE AS A MUCOLYTIC AGENT OR EXPECTORANT - Methods and devices for treating excess mucus accumulation in mammals by administering gaseous inhaled nitric oxide or nitric oxide releasing compounds as a mucolytic agent or expectorant are provided. Delivery of gaseous nitric oxide can be made nasally or orally and is preferably substantially coincident with inhalation of the mammal or based on a synchronous parameter of the mammal's respiratory cycle. Varying therapeutic profiles may be used for the delivery of gaseous nitric oxide depending on the severity of the excess mucus accumulation. Parameters for the therapeutic profiles may include flow rate of nitric oxide containing gas, duration of administration of nitric oxide containing gas, number of breaths for which nitric oxide containing gas is to be administered, and concentrations of therapeutic NO delivered to the airways. | 2014-05-22 |
20140141099 | DRUG DISCOVERY METHODS - The present invention relates to drug discovery methods, particularly methods for assaying compounds for activity as Aurora kinase inhibitors. This invention also relates to a pharmacophore describing compounds that are able to promote a conformational change in the protein AuroraB and whose binding constant for the two-step process is given as Ki*. Finally, this invention also relates to compounds having the features of the pharmacophore. | 2014-05-22 |
20140141100 | Compounds and Methods for Appetite Suppression and Weight Control - Disclosed is a method of treating obesity, reducing weight, preventing weight gain, and/or suppressing appetite in a subject in need thereof by administering topically a pharmaceutical compound having a chemotherapeutic agent to at least a surface of the subject's mouth. The method includes inhibiting taste cell reproduction on the surface of the subject's mouth with the compound and reducing sense of taste, appetite for food in the subject, or a combination thereof. | 2014-05-22 |
20140141101 | COMPOSITIONS OF ENHANCING WOUND HEALING CONTAINING MAGNESIUM AND BROMIDE - The present invention relates to ionic compositions for enhancing wound healing, particularly in the sinonasal cavity. The ionic components of the composition can include potassium, calcium, rubidium, zinc, bromide, and magnesium in an isotonic solution. In other embodiments, the ionic components of the composition can include magnesium, bromide, sulfate, sodium, and chloride. Methods of enhancing wound healing, enhancing sinonasal mucosal healing, promoting mucosal reciliation, and debriding tissue by administering the compositions of the present invention are also presented. | 2014-05-22 |
20140141102 | TRIMEGESTONE (TMG) FOR TREATMENT OF PRETERM BIRTH - As disclosed herein, novel compositions including steroid hormones, such as trimegestone (TMG) and progesterone (P4), provide treatments for term and preterm labor with significant effects on the delay of delivery. Delay and block of delivery occurs when both P4 and TMG are administered late in gestation in pregnant rat and guinea pig animal models. TMG exhibits remarkable drug efficacy, achieving the same inhibition as P4, but at much lower doses. These hereto unknown effects of TMG on the processes of cervical ripening and uterine contraction provide a novel approach for extending pregnancy term, including reducing a likelihood of preterm and/or term labor, along with improved methods of administration. Other diseases and/or conditions may be treated with TMG, such as dysmenorrhea or luteal insufficiency for sustaining pregnancy. | 2014-05-22 |
20140141103 | METHODS OF TREATING HEPATITIS - The present invention relates to a method of treating hepatitis in a patient, which includes administering a pharmaceutical composition that includes carbon monoxide to the patient. | 2014-05-22 |
20140141104 | TREATMENT OF NEURODEGENERATIVE DISEASES - Use of selenate or a pharmaceutically acceptable salt thereof in methods and compositions for enhancing the activity of the protein phosphatase PP2A is provided. Methods of reducing phosphorylation of tau protein, inhibiting activity of GSK3 and treating or preventing neurodegenerative diseases are also described. | 2014-05-22 |
20140141105 | SONICALLY FORMED TRICHOMIC EXTRACT MATERIAL - A process, product, and product by process related to sonic welding, for quickly, compressing, shaping, and decarboxylating cannabinoids; preferably from | 2014-05-22 |
20140141106 | ARTIFICIAL TEARS AND THERAPEUTIC USES - The present invention provides ophthalmic compositions, e.g. artificial tears, suitable for treating dry eye syndrome in a human or other mammal suffering there from, e.g. a dog or cat, which comprise a mixture of castor oil with another oil, e.g. a food oil, e.g. olive oil, sesame oil, corn oil etc. | 2014-05-22 |